SRI has developed a promising new treatment for this cancer of the immune system that affects plasma cells in bone marrow.
SRI is conducting preclinical development of treatments for diseases such as tuberculosis, West Nile virus, hepatitis, and biodefense pathogens and toxins.
SRI’s Brown Laboratory is utilizing cell-targeting peptides to deliver active therapeutic cargo to specific cells in vivo.
Novel molecular targets of several cytokines are being evaluated by SRI scientists, with the goal of designing a small-molecule drug to block responses involved in many of these inflammatory diseases.
SRI is developing a novel point-of-care tool for the early detection of devastating diseases.
SRI’s Brown Laboratory is using selected peptides as “fishing hooks” to identify novel cell surface features.
Through a broad range of services for the National Institutes of Health, SRI is accelerating preclinical development of potential therapies for diseases that affect millions of people.
SRI's Brown Laboratory is taking multiple approaches to develop effective anti-cancer immunotherapies.
SRI is analyzing the genetics of smoking and related characteristics, using data from a large-scale National Cancer Institute study on smoking cessation.
SRI established the Twin Research Registry as part of its scientific research and efforts to discover more about human behavior. Fraternal and identical twins and multiples of all ages are invited to join the Registry for consideration for research studies.
To help prepare for next-generation pandemics, SRI is partnering with Stanford University to examine vaccination responses.
Vitamin A deficiency causes susceptibility — especially in children — to diarrhea-causing infections, which lead to millions of deaths each year. SRI is developing a probiotic that produces the vitamin.